<DOC>
	<DOC>NCT00691808</DOC>
	<brief_summary>The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).</brief_summary>
	<brief_title>Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment</brief_title>
	<detailed_description />
	<mesh_term>Memory Disorders</mesh_term>
	<criteria>Males and females aged 6080 years old. Complaints of memory loss in everyday life Nonsmokers or very light smokers (no more than 10 cigarettes/day) Negative urine screen for drugs of abuse Ability to provide written informed consent History or evidence of any disease, disorder or injury that could cause cognitive deterioration. Need for medications other than hormone replacement therapy, daily vitamins, or overthecounter pain killers Clinically significant abnormality on electrocardiogram History of alcoholism or drug dependence Use of dietary supplements containing Huperzine A, gingko biloba, phosphatidylserine, or Docosahexaenoic acid (DHA)</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>